George Magrath

Company: Ocuphire Pharma

Job title: CEO

Seminars:

APX3330: A Clinically Staged Non-Invasive Oral Therapy for Diabetic Retinopathy 10:00 am

Phase 2 clinical trial results in a placebo-controlled trial showing promising therapeutic potential Discussing the biology of Ref-1 and inhibition using APX3330, a first in class agent Exploring the promise of DR clinical trials with an oral therapyRead more

day: Conference Day 1

Panel Discussion: State of Play of Retinal Vascular Drug Development 9:00 am

What are the unique challenges of developing safe and efficacious drugs for Wet AMD vs DR vs DME? How are these different from the challenges when developing therapeutics for Dry AMD and GA? What do the current clinical pipelines look like for Wet AMD vs DR vs DME vs RVO? What does the future of…Read more

day: Conference Day 1